Group 1 - The core announcement is regarding China Health Group's rights issue, where shareholders will receive 3 shares for every 10 shares held at an issue price of HKD 0.10 per share [1] - As of the record date, the company received a total of 10 valid acceptances for a total of 120 million rights shares, which represents approximately 81.1% of all rights shares available [1] - The shortfall in subscriptions amounts to 27.8 million rights shares, approximately 18.9% of the total rights shares [1] Group 2 - The unallocated rights shares will be handled according to the compensation arrangement, with Mr. Zhang and underwriters subscribing to 390,000 and 40.8 million rights shares, respectively [1] - There were no ineligible shareholders as of the record date, resulting in zero unallocated rights shares for ineligible shareholders [1] - All unallocated rights shares were successfully placed to four independent subscribers at the same price of HKD 0.10 per share, leading to no net proceeds available for distribution to non-participating shareholders [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示概不會就本公佈全部或任何部分內容產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 China Health Group Limited 中國衛生集團有限公司 （以CHG HS Limited名稱在香港經營業務） （於百慕達註冊成立之有限公司） （股份代號：673） (I)按於記錄日期每持有十(10)股股份獲發三(3)股供股股份之基準進行供股之結果； 及 (II)購股權計劃項下尚未行使之購股權之調整 茲提述(i)中國衛生集團有限公司（「本公司」）日期為二零二五年七月三十一日有關建議之通函 （「通函」）；(ii)本公司日期為二零二五年九月三日之供股章程（「供股章程」），內容有關按於記錄日 期每持有十(10)股股份獲發三(3)股供股股份之基準按發行價每股供股股份0.10港元進行供股；(iii) 本公司日期為二零二五年九月二十二日之公佈，內容有關供股股份之有效接納結果以及補償安 排涉及之未獲認購供股股份數目（「該公佈」）；及(iv)本公司日期為二零二五年九月二十四日之公 佈，內容有關因惡劣天氣修 ...

致：香港交易及結算所有限公司 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 呈交日期: 2025年10月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00673 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 100,000,000,000 | HKD | | 0.1 HKD | | 10,000,000,000 | | 增加 / 減少 (-) | | | 0 | | | HKD | | 0 | | 本月底結存 | | | 100,000,000,000 | HKD | | 0.1 HKD | | 10,000,000,000 | 公司名稱: 中國衛生集團有限公司 ( 以 CHG HS Li ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示概不會就本公佈全部或任何部分內容產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 China Health Group Limited 中國衛生集團有限公司 （以CHG HS Limited名稱在香港經營業務） （於百慕達註冊成立之有限公司） （股份代號：673） 於二零二五年九月二十六日舉行之股東週年大會投票表決結果 於股東週年大會上，股東週年大會通告所載於股東週年大會動議之所有決議案均已獲出席股東週 年大會並於會上投票之股東以點票表決方式正式通過。 茲提述本公司於二零二五年七月二十四日刊發有關股東週年大會之通函（「該通函」）。除文義另有 所指外，本公佈所用詞彙與該通函中所界定者具有相同涵義。 董事會欣然宣佈，於二零二五年九月二十六日上午十一時正在香港中環德輔道中141號中保集團 大廈8樓801室舉行之股東週年大會上，股東週年大會通告所載於股東週年大會動議之所有決議 案，均已獲出席股東週年大會並於會上投票之股東以點票表決方式正式通過。 – 1 – 股東週年大會之投票表決結果如下： (a ...

（以CHG HS Limited名稱在香港經營業務） （於百慕達註冊成立之有限公司） （股份代號：673） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示概不就因本公佈全部或任何部分內容而產生或因依賴該等 內容而引致之任何損失承擔任何責任。 本公佈僅作參考之用，並不構成收購、購買或認購本公司證券之邀請或要約。 China Health Group Limited 中國衛生集團有限公司 關於 (I)根據特別授權認購新股份； 及 (II)建議按於記錄日期每持有十(10)股股份 獲發三(3)股供股股份之基準進行供股之 經修訂預期時間表 茲提述(i)中國衛生集團有限公司（「本公司」）日期為二零二五年七月三十一日有關建議之通函 （「通函」）；(ii)本公司日期為二零二五年九月三日之供股章程，內容有關按於記錄日期每持有十 (10)股股份獲發三(3)股供股股份之基準按發行價每股供股股份0.10港元進行供股；及(iii)本公司 日期為二零二五年九月二十二日之公佈，內容有關供股股份之有效接納結果以及補償安排涉及之 未獲認購供股股份數目（「該公佈」）。除文 ...

Group 1 - The total number of shares offered under the rights issue by China Health Group (00673) is 147 million shares [1] - As of the deadline on September 17, 2025, a total of 10 valid acceptances were received, involving 120 million shares, which accounts for approximately 81.1% of all offered shares [1] - The shortfall in subscriptions amounts to 27.8036 million shares, representing about 18.9% of all offered shares, which will be handled according to the compensation arrangement [1] Group 2 - Mr. Zhang and the underwriters have committed to subscribe for 392,200 shares and 40.7976 million shares, respectively [2] - The placement agent will make efforts to ensure that the acquirers subscribe for all unsold and unclaimed shares at no less than the issue price by September 24, 2025 [2] - According to the terms of the underwriting agreement, any unsold and unclaimed shares under the compensation arrangement will be purchased by the underwriters [2]

格隆汇9月22日丨中国卫生集团(00673.HK)公告，供股项下提呈发售供股股份总数为147,493,428股。董 事会宣布，于2025年9月17日(星期三)下午四时正(即最后接纳时限)，已接获合共10份有效接纳，涉及合 共119,689,791股供股股份，约占所有供股股份的81.1%。因此，供股认购不足额为27,803,637股供股股 份，约占所有供股股份的18.9%，并将根据补偿安排处理。根据契诺契约及承诺，张先生及包销商分别 认购392,220股及40,797,600股供股股份。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示概不會就本公佈全部或任何部分內容產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 China Health Group Limited 中國衛生集團有限公司 （以CHG HS Limited名稱在香港經營業務） （於百慕達註冊成立之有限公司） （股份代號：673） (1)供股股份之有效接納結果； 及 (2)補償安排涉及之未獲認購供股股份數目 茲提述中國衛生集團有限公司（「本公司」）日期為二零二五年九月三日之供股章程（「供股章程」）， 內容有關按於記錄日期每持有十(10)股股份獲發三(3)股供股股份之基準按發行價每股供股股份 0.10港元進行供股。除文義另有所指外，本公佈所用詞彙與供股章程所界定者具有相同涵義。 供股股份之有效接納結果 供股項下提呈發售之供股股份總數為147,493,428股。 董事會宣佈，於二零二五年九月十七日（星期三）下午四時正（即最後接納時限），已接獲合共10份 有效接納，涉及合共119,689,791股供股股份，約佔所有供股股份的81.1%。因此，供股認購不足額 為 ...

Group 1 - Dongyangguang plans to jointly increase capital in a subsidiary for the acquisition of 100% equity in Qinhuai Data China, with a total investment of 75 billion yuan [2] - Baiyin Nonferrous Metals is under investigation by the China Securities Regulatory Commission for suspected information disclosure violations [3] - Beida Pharmaceutical intends to issue H-shares and apply for listing on the Hong Kong Stock Exchange [5] Group 2 - ST Tianmao plans to withdraw its A-share listing and transfer to the National SME Share Transfer System after delisting [5] - Goldwind Technology has approved an investment agreement for a 3GW wind-hydrogen-ammonia integration project in Inner Mongolia, with a total investment of approximately 189.2 billion yuan [6] - Langzi Co. has signed an agreement to acquire 67.5% of Chongqing Milan Baiyu Shiguang Medical Beauty Hospital for 92.475 million yuan [7] Group 3 - Dongfang Guoxin is establishing a joint venture with Beijing Shunyi Financial Holdings to focus on computing power infrastructure and services, with a registered capital of 300 million yuan [8] - ST Hezhong's chairman is under bail pending trial, but the company's operations remain unaffected [9] - Kangzhi Pharmaceutical's major shareholder is transferring 22.758 million shares at a price of 5.34 yuan per share, totaling 122 million yuan [9] Group 4 - Shenzhen Airport reported a passenger throughput of 5.807 million in August, a year-on-year increase of 4.07% [10] - Lin Yang Energy won a bid for a project with a total amount of approximately 244.08 million yuan [11] - Fullpower New Materials received a government subsidy of 20 million yuan, which is expected to positively impact its 2025 profits [14] Group 5 - BYD executives and core personnel collectively increased their holdings by 48.82 million shares, totaling 52.3278 million yuan [16] - Hualing Steel's major shareholder increased its stake by 6.90862 million shares, representing a 1% increase in ownership [16]

Group 1 - Dongyangguang announced a capital increase of 35 billion and 40 billion yuan for Dongshu Yihua, resulting in ownership stakes of 46.6654% and 53.3332% respectively after the increase [1] - Dongshu Yihua plans to invest the raised funds into its wholly-owned subsidiary, Shanghai Dongchuang Future Data Co., which will further invest in Dongshu Sanhao for the acquisition of 100% equity of Qinhuai Data China for 28 billion yuan [1] - After the completion of these transactions, Dongyangguang will become a shareholder of Dongshu Yihua, indirectly holding a portion of Qinhuai Data China's equity [1] Group 2 - Qinhuai Data is recognized as a leading player in the computing power sector, ranking first in three major indices: intensive development, international layout, and green low-carbon [5] - As of May 2023, Qinhuai Data's total assets were 21.871 billion yuan, with net assets of 9.504 billion yuan, and projected revenue of 6.048 billion yuan and net profit of 1.309 billion yuan for 2024 [6][7] - The acquisition of Qinhuai Data's assets is seen as a strategic move for Dongyangguang to quickly enter the data center field, enhancing its long-term competitiveness and investment value [7] Group 3 - The acquisition is part of a broader strategy to align with the national "East Data West Calculation" initiative, aiming to build a unified national computing power network [7] - Dongyangguang's technological capabilities in liquid cooling materials and supercapacitors provide a unique advantage in delivering core solutions for high-density AI computing scenarios [6] - The competitive bidding for Qinhuai Data's assets reflects strong market recognition of its value and the prospects of the national computing power strategy [5]